Zevra Therapeutics, Inc.
DE ˙ DB ˙ US4884452065
9,46 € ↑0,16 (1,72%)
2026-06-05
PREZZO DELLE AZIONI
SecurityDE:1GDA / Zevra Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership100,135 shares
Latest Disclosed Value $ 897,210
Barclays Plc reports 69.88% decrease in ownership of 1GDA / Zevra Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 100,135 shares of Zevra Therapeutics, Inc. (DE:1GDA) valued at $740,999 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 332,443 shares of Zevra Therapeutics, Inc.. This represents a change in shares of -69.88% during the quarter. The current value of the position is $947,277 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F ZEVRA THERAPEUTICS COM 488445206 100,135 -232,308 -69.88 897 -71.62 0.0002
2026-03-31 2025-09-30 13F/A-3 ZEVRA THERAPEUTICS COM 488445206 332,443 228,092 218.58 3,162 243.96 0.0007
2026-03-19 2025-09-30 13F/A-2 ZEVRA THERAPEUTICS COM 488445206 57,599 -46,752 400 0.0001
2025-11-12 2025-09-30 13F ZEVRA THERAPEUTICS COM 488445206 332,443 228,092 3,162 0.0007
2026-02-27 2025-06-30 13F/A-2 ZEVRA THERAPEUTICS COM 488445206 104,351 -330,339 -75.99 919 -71.77 0.0002
2025-08-14 2025-06-30 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 104,351 -330,339 1 0.0002
2025-08-13 2025-06-30 13F ZEVRA THERAPEUTICS COM 488445206 104,351 -330,339 1 0.0001
2026-03-17 2025-03-31 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 434,690 145,002 50.05 3,256 34.78 0.0009
2025-05-15 2025-03-31 13F ZEVRA THERAPEUTICS COM 488445206 434,690 145,002 3 0.0009
2026-03-19 2024-12-31 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 289,688 232,089 402.94 2,416 505.26 0.0007
2025-02-13 2024-12-31 13F ZEVRA THERAPEUTICS COM 488445206 289,688 232,089 2 0.0007
2026-03-31 2024-09-30 13F/A-2 ZEVRA THERAPEUTICS COM 488445206 57,599 42,926 292.55 400 461.97 0.0001
2024-11-19 2024-09-30 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 57,599 42,926 0 0.0001
2024-11-15 2024-09-30 13F ZEVRA THERAPEUTICS COM 488445206 57,599 42,926 0 0.0000
2026-03-23 2024-06-30 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 14,673 -10,933 -42.70 72 -52.03 0.0000
2024-08-14 2024-06-30 13F ZEVRA THERAPEUTICS COM 488445206 14,673 -10,933 0 0.0000
2026-03-24 2024-03-31 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 25,606 -24,391 -48.78 149 -54.74 0.0001
2024-05-15 2024-03-31 13F ZEVRA THERAPEUTICS COM 488445206 25,606 -24,391 0 0.0001
2026-03-25 2023-12-31 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 49,997 44,032 738.17 327 1,067.86 0.0001
2024-02-15 2023-12-31 13F ZEVRA THERAPEUTICS COM 488445206 49,997 44,032 0 0.0001
2026-03-26 2023-09-30 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 5,965 -971 -14.00 29 -20.00 0.0000
2023-11-07 2023-09-30 13F ZEVRA THERAPEUTICS COM 488445206 5,965 -971 0 0.0000
2026-03-30 2023-06-30 13F/A-2 ZEVRA THERAPEUTICS COM 488445206 6,936 6,827 6,263.30 35 0.0000
2023-09-20 2023-06-30 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 6,936 6,827 0 0.0000
2023-08-03 2023-06-30 13F ZEVRA THERAPEUTICS COM 488445206 6,936 6,827 0 0.0000
2026-03-30 2023-03-31 13F/A-1 ZEVRA THERAPEUTICS COM 488445206 109 -244 -69.12 1 -100.00 0.0000
2023-05-04 2023-03-31 13F ZEVRA THERAPEUTICS COM 488445206 109 -244 0 0.0000
2026-03-30 2022-12-31 13F/A-1 KEMPHARM COM 488445206 353 -1,304 -78.70 2 -90.00 0.0000
2023-02-13 2022-12-31 13F KEMPHARM COM 488445206 353 -1,304 0 0.0000
2022-11-03 2022-09-30 13F KEMPHARM COM 488445206 1,657 1,657 10 0.0000
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.